Azurity Pharmaceuticals announced FDA approval of Danziten (nilotinib) tablets, the first nilotinib formulation without mealtime restrictions, for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase, and for those with chronic or acute phase CML resistant or intolerant to prior imatinib therapy.
Richard Blackburn, CEO of Azurity Pharmaceuticals, stated that Danziten offers equivalent efficacy to Tasigna but removes the fasting requirement, potentially improving patient adherence. Tasigna, while effective, has variable bioavailability significantly increased by food intake, leading to potential QT interval prolongation and cardiotoxicity if not taken in a fasted state.
Danziten is a re-engineered formulation of nilotinib designed to maintain consistent pharmacokinetics regardless of food intake, allowing for a lower dose while preserving efficacy. With optimal tyrosine kinase inhibitor (TKI) therapy, CML patients can achieve deep molecular responses and potentially treatment-free remission. Challenges remain in patient adherence, which Danziten aims to address by removing fasting requirements.
Danziten will be available in the coming weeks through Biologics by McKesson and Limited Specialty Distribution. Azurity will also offer patient support through the DanzitenCONNECT program, which includes prior authorization support, benefits investigation, a free first month of Danziten, co-pay assistance, and a patient assistance program.
Impact on CML Treatment
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome, a translocation between chromosomes 9 and 22, resulting in the BCR-ABL1 fusion gene. This gene encodes an abnormal tyrosine kinase that drives the proliferation of myeloid cells. The introduction of tyrosine kinase inhibitors (TKIs) like imatinib has dramatically improved the prognosis for CML patients, transforming it from a fatal disease to a chronic condition manageable with oral medication.
The Need for Improved Adherence
Despite the effectiveness of TKIs, adherence to treatment remains a significant challenge. Studies have shown that suboptimal adherence can lead to treatment failure and disease progression. The strict fasting requirements associated with some TKIs, such as Tasigna, can further complicate adherence. Danziten's formulation removes this barrier, potentially leading to better patient outcomes.
Clinical Significance
The approval of Danziten represents a significant advancement in the treatment of CML. By eliminating the need for fasting, Danziten offers patients a more convenient and manageable treatment option, potentially improving adherence and long-term outcomes. This is particularly important given that the life expectancy of newly diagnosed CML patients who respond to appropriate treatment is now approaching that of the general population.
